Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark Jones, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
140 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Canberra Hospital
Garran, Australian Capital Territory, Australia
- Calvary Mater Newcastle
Waratah, New South Wales, Australia
- Westmead Hospital
Westmead, New South Wales, Australia
- Cabrini Health
Malvern, Victoria, Australia
- Fiona Stanley Hospital
Murdoch, Australia
- Centro de Pesquisa Porto Alegre
Porto Alegre, Florianopolis, Brazil
- Fundacao Pio Xii - Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
- Hospital Sao Jose
São Paulo, São Paulo, Brazil
- Instituto Do Cancer de Sao Paulo - Icesp
São Paulo, São Paulo, Brazil
- Centro Avancado de Tratamento Oncologico - Cenantron -
Belo Horizonte, Brazil
- Hospital de Clinicas de Porto Alegre
Porto Alegre, Brazil
- Tom Baker Cancer Centre
Calgary, Alberta, Canada
- Kingston Health Sciences Centre - Kgh Site
Kingston, Ontario, Canada
- Sunnybrook Health Sciences, Odette Cancer Centre
Toronto, Ontario, Canada
- Jewish General Hospital
Montreal, Quebec, Canada
- Chu de Quebec-Universite Laval-Hotel Dieu de Quebec
Québec, Quebec, Canada
- Ciusss de la Mauricie-Et-Du-Centre-Du-Quebec
Trois-Rivières, Quebec, Canada
- Clinica Alemana de Osorno
Osorno, Los Lagos Region, Chile
- Fundacion Arturo Lopez Perez Falp
Santiago, Chile
- Pontificia Universidad Catolica de Chile
Santiago, Chile
- Hospital Clinico Vina del Mar
Viña del Mar, Chile
- Centre Antoine Lacassagne
Nice, Cedex 2, France
- Chu Besancon - Hopital Jean Minjoz
Besançon, France
- Hopital Saint Andre
Bordeaux, France
- Centre Francois Baclesse
Caen, France
- Hopital Prive Toulon Hyeres Sainte Marguerite
Hyères, France
- Hopital Europeen Georges Pompidou
Paris, France
- Hospices Civils de Lyon Centre Hospitalier Lyon Sud
Pierre-Bénite, France
- Chu de Strasbourg - Nouvel Hopital Civil
Strasbourg, France
- Clinique Sainte Anne
Strasbourg, France
- Institut Gustave Roussy
Villejuif, France
- Helios Klinikum Berlin Buch
Berlin, Germany
- Universitaetsklinikum Der Technischen Universitaet Dresden
Dresden, Germany
- Universitaetsklinikum Essen
Essen, Germany
- Universitaetsklinikum Frankfurt
Frankfurt am Main, Germany
- Medizinische Hochschule Hannover
Hanover, Germany
- Universitaetsklinikum Jena
Jena, Germany
- Universitaetsklinikum Magdeburg. Klinik Fuer Urologie
Magdeburg, Germany
- Universitaetsklinikum Tuebingen
Tübingen, Germany
- Orszagos Onkologiai Intezet
Budapest, Pest County, Hungary
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Dec 2017
- Primary completion
- 22 Aug 2018
- Completion
- 4 Jun 2025
- Last update posted
- 22 May 2026
- Registered enrollment
- 129
- Registry id
- NCT03260894
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.